The Frequency of Resistance to Synthetic Erythropoietin and Its Risk Factors among Chronic Hemodialysis Patients in Kerman

Document Type: Original Article

Authors

1 Nephrologist, Assistant Professor, Shafa Clinical Research Committee, Kerman University of Medical Sciences, Kerman, Iran

2 Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran

3 Internal Medicine, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

4 Dialysis Center Nurse, Shafa Clinical Research Committee, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Background: The aim of this study was to determine the frequency of resistance to synthetic erythropoietin and factors affecting it among chronic hemodialysis patients in Kerman/ Iran.
Methods: This cross- sectional study was performed on chronic hemodialysis patients of three hemodialysis centers in Kerman, Iran during 3 successive months in the summer of 2016. Women with hemoglobin less than 11 and men with hemoglobin less than 12 were included in the study and using medical records, their sex, age, hemoglobin level, the amount of administered erythropoietin, tests of ferritin profile, and CPR and PTH levels were extracted and entered in a questionnaire. Patients were divided into the two groups of resistant to medication (received 300 units or more erythropoietin for each kilogram body weight in week for reaching the target hemoglobin) and the group who did not have resistance. Then, the two groups were compared in terms of mentioned factors.
Results: The frequency of resistance to synthetic erythropoietin was generally 33.66% and it was 32.4%in females and 67.6% in males that shows no significant difference between the two sexes (p=0.079). Among the studied factors, low ferritin level (P=0.012) and CRP level (p= 0.001) showed significant relationship with resistance to erythropoietin.
Conclusion: Since, iron- deficiency anemia presented with low ferritin level, and high CRP level which indicates infection and inflammation had the greatest relationship with resistance to synthetic erythropoietin, removing causes of infection and iron-deficiency anemia in hemodialysis patients in order to reduce the use of costly synthetic erythropoietin is recommended.

Keywords


  1. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.J Am Soc Nephrol 2006; 17(4):1181-91.
  2. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, et al. Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 2002; 40(1):27-33.
  3. Al-Ageel NA, Al-Aqeel SA, Abanmy NO, Alwakeel JS, Sabry A, Alsaran KA. Appropriateness of anemia management in hemodialysis patients. Saudi Pharm J 2012; 20(1):85-91.
  4. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38(4):803-12.
  5. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008(111):S75–81.
  6. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis. 4th ed,USA; 2007.     
  7. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30(4 Suppl 3):S192-240.
  8. DeAngelo AJ, Bell DG, Quinn MW, Long DE, Ouellette DR. Erythropoietin response in critically ill mechanically ventilated patients: a prospective observational study.Crit Care 2005; 9(3): 172–6.
  9. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA, et al. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 2007; 578(Pt 1):309-14.
  10. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25(4):548-54.
  11. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.Ann Intern Med 2010; 153(1):23-33.
  12. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316(2):73-8.
  13. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006; 151(2):492-500.
  14. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141(1):14-31.
  15. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24(4):1082-8.
  16. Liu J, Guo H, Gilbertson D, Foley R, Collins A. Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis. Ther Clin Risk Manag 2009; 5(4):319-30.
  17. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al.Prevalence of chronic kidney disease in the United States. JAMA 2007; 298(17):2038-47.
  18. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1-47.
  19. Ribeiro S, Costa E, Belo L, Santos-Silva A. rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits. Hemodialysis intech 2013; 16:291-6 (http://semanticscholar.org/paper)
  20. Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 2011; 80(5):464-
  21. Di Iorio BR, Stellato D, De Santo NG, Cirillo M; Campanian Dialysis Registry Research Group. Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif 2004; 22(5):423-7.
  22. Daqing Hong. Erythropoietin hyporesponsiveness is more likely among female than male hemodialysis patients (HD).Adv Chronic Kidney Dis. 2015; 17(1):111..(https://www.renalandurologynews)
  23. Alves MT, Vilaça SS, Carvalho Md, Fernandes AP, Dusse LM, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter 2015; 37(3):190-7.
  24. Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts.Pediatr Nephrol 2009; 24(3):571-9.
  25. Lea JP, Norris K, Agodoa L. The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol 2008; 28(5):732-43.
  26. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42(5):864-81.
  27. Bamgbola O. Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 2012; 27(2):195-205.
  28. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004; 65(5):1864-9.
  29. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11(3):530-8.
  30. Lin CL, Hung CC, Yang CT, Huang CC. Improved Anemia and Reduced Erythropoietin Need by Medical or Surgical Intervention of Secondary Hyperparathyroidism in Hemodialysis Patients. Renal Failure 2004; 26(3):289-95.
  31. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328(3):171-5.
  32. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26(8):2641-8.
  33. El-Khatib M, Duncan HJ, Kant KS. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. Nephrology (Carlton) 2006; 11(5):400-4.
  34. Nand N, Chugh M, Sharma M. Effect of erythropoietin on highly sensitive C - reactive protein levels in cases of chronic kidney disease undergoing maintenance hemodialysis. JIMSA 2011; 12(3): 182-6.
  35. Bárány P, Divino Filho JC, Bergström J.High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29(4):565-8.